NCT05268198View on ClinicalTrials.gov

SAD Study of APR002 Investigating the Safety/Tolerability, Pharmacokinetics/Pharmacodynamics in Healthy Subjects

EARLY_PHASE1CompletedINTERVENTIONAL
Enrollment

42

Participants

Timeline

Start Date

March 20, 2023

Primary Completion Date

June 29, 2023

Study Completion Date

July 27, 2023

Conditions
COVID-19
Interventions
DRUG

APR002

Active Investigational Product

DRUG

Placebo

Placebo

Trial Locations (1)

5000

CMAX Clinical Research, Adelaide

Sponsors
All Listed Sponsors
collaborator

CMAX Clinical Research Pty Limited

UNKNOWN

collaborator

Avance Clinical Pty Ltd.

INDUSTRY

lead

Global Health Drug Discovery Institute

OTHER